Cargando…
State-of-the-art treatment of metastatic renal cell carcinoma
Targeted therapy has greatly changed the way in which metastatic renal cell carcinoma (rcc) is treated. Agents that inhibit the vascular endothelial growth factor and mammalian target of rapamycin pathways that otherwise lead to angiogenesis have now become the standard of care. Much research into t...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Multimed Inc.
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687801/ https://www.ncbi.nlm.nih.gov/pubmed/19478897 |